In a recent development, Citigroup has initiated coverage on Acumen Pharmaceuticals (ABOS) with a 'Buy' rating, as reported on June 17, 2025. This move highlights Citigroup's positive outlook on the potential growth and market position of Acumen Pharmaceuticals.\n\nAcumen Pharmaceuticals has been assigned a price target of $4.00 USD by analyst Geoff Meacham. This marks the first price target and rating provided by Citigroup for Acumen Pharmaceuticals, as there was no prior coverage or price target to report a percentage change.\n\nThe 'Buy' rating suggests confidence in Acumen Pharmaceuticals by Citigroup, forecasting that the stock could perform well in the market. Investors and market watchers might find this update noteworthy as it could influence trading decisions and market perceptions about Acumen Pharmaceuticals.\n\nBased on the one-year price targets offered by 4 analysts, the average target price for Acumen Pharmaceuticals Inc is $8.75 with a high estimate of $11.00 and a low estimate of $4.00. The average target implies an upside of 667.54% from the current price of $1.14. More detailed estimate data can be found on the Acumen Pharmaceuticals Inc Forecast page.\n\nBased on the consensus recommendation from 5 brokerage firms, Acumen Pharmaceuticals Inc's average brokerage recommendation is currently 1.4, indicating 'Buy' status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Citigroup Initiates Coverage on Acumen Pharmaceuticals (ABOS) with 'Buy' Rating | ABOS Stock News

Citigroup has initiated coverage on Acumen Pharmaceuticals (ABOS) with a 'Buy' rating, assigning a price target of $4.00 USD. Analysts' average target price is $8.75, implying a 667.54% upside from the current price of $1.14. The average brokerage recommendation is 1.4, indicating 'Buy' status.